|
gptkbp:instanceOf
|
gptkb:drug
gptkb:long-acting_insulin
|
|
gptkbp:administeredOnceDaily
|
true
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:ATCCode
|
A10AE04
|
|
gptkbp:biosimilar
|
true
|
|
gptkbp:brand
|
gptkb:Basaglar
gptkb:Lantus
gptkb:Toujeo
|
|
gptkbp:CASNumber
|
160337-95-1
|
|
gptkbp:contraindication
|
hypersensitivity to insulin glargine
|
|
gptkbp:discoveredBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:eliminationHalfLife
|
~12-19 hours
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:hasMolecularFormula
|
C267H404N72O78S6
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly
gptkb:Sanofi
|
|
gptkbp:mechanismOfAction
|
insulin receptor agonist
|
|
gptkbp:notForInsulinPump
|
true
|
|
gptkbp:notForIVUse
|
true
|
|
gptkbp:onset
|
1-2 hours
|
|
gptkbp:patentExpired
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
recombinant human insulin analogue
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
weight gain
injection site reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
type 1 diabetes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Biocon_Biologics
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Insulin Glargine
|